Contezolid free base
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413268

CAS#: 1112968-42-9

Description: Contezolid (Youxitai ®), an orally administered oxazolidinone antibacterial agent, is being developed by Shanghai MicuRx Pharmaceutical Co., Ltd. for the treatment of multidrug-resistant (MDR) Gram-positive bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci. In June 2021, it was approved by the National Medical Products Administration of China for the treatment of complicated skin and soft tissue infections (cSSTI), including, but not limited to, methicillin-susceptible S. aureus, MRSA, Streptococcus pyogenes and Streptococcus agalactiae. The recommended dosage of contezolid is 800 mg (i.e. two 400 mg tablets) every 12 h for 7-14 days. Contezolid is also undergoing clinical development for acute bacterial skin and skin structure infections (ABSSSI) in the USA, and for diabetic foot infections.

Chemical Structure

img
Contezolid free base
CAS# 1112968-42-9
Instruction

Theoretical Analysis

MedKoo Cat#: 413268
Name: Contezolid free base
CAS#: 1112968-42-9
Chemical Formula: C18H15F3N4O4
Exact Mass: 408.10
Molecular Weight: 408.340
Elemental Analysis: C, 52.95; H, 3.70; F, 13.96; N, 13.72; O, 15.67

Price and Availability

Size Price Availability Quantity
5mg USD 1250 2 Weeks
Bulk inquiry

Related CAS #: 1112968-42-9   1807365-35-0 (sodium)   1807497-11-5 (free acid),  

Synonym: Contezolid Free Base; MRX1; MRX 1; MRX-1

IUPAC/Chemical Name: 4(1H)-Pyridinone, 2,3-dihydro-1-(2,3,6-trifluoro-4-((5S)-5-((3-isoxazolylamino)methyl)-2-oxo-3-oxazolidinyl)phenyl)-

InChi Key: SULYVXZZUMRQAX-NSHDSACASA-N

InChi Code: InChI=1S/C18H15F3N4O4/c19-12-7-13(15(20)16(21)17(12)24-4-1-10(26)2-5-24)25-9-11(29-18(25)27)8-22-14-3-6-28-23-14/h1,3-4,6-7,11H,2,5,8-9H2,(H,22,23)/t11-/m0/s1

SMILES Code: O=C1CCN(C2=C(F)C=C(N3C(O[C@@H](CNC4=NOC=C4)C3)=O)C(F)=C2F)C=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
Soluble in DMSO 0.0 100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 408.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Hoy SM. Contezolid: First Approval. Drugs. 2021 Sep;81(13):1587-1591. doi: 10.1007/s40265-021-01576-0. Erratum in: Drugs. 2021 Nov;81(16):1945. PMID: 34365606; PMCID: PMC8536612.


2: Kaul G, Dasgupta A, Chopra S. Contezolid in complicated skin and soft tissue infection. Drugs Today (Barc). 2022 Jul;58(7):315-326. doi: 10.1358/dot.2022.58.7.3389002. PMID: 35851867.


3: Hoy SM. Correction to: Contezolid: First Approval. Drugs. 2021 Nov;81(16):1945. doi: 10.1007/s40265-021-01627-6. Erratum for: Drugs. 2021 Sep;81(13):1587-1591. PMID: 34687423; PMCID: PMC9172673.


4: Yuan H, Wu H, Zhang Y, Huang H, Li Y, Wu J, Cao G, Yu J, Guo B, Wu J, Yuan Z, Chen Y, Yang W, Wu X, Zhang J. Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections. Antimicrob Agents Chemother. 2022 Jun 21;66(6):e0243021. doi: 10.1128/aac.02430-21. Epub 2022 May 16. PMID: 35575579; PMCID: PMC9217102.


5: Guo Q, Xu L, Tan F, Zhang Y, Fan J, Wang X, Zhang Z, Li B, Chu H. A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0088921. doi: 10.1128/AAC.00889-21. Epub 2021 Aug 30. PMID: 34460305; PMCID: PMC8522767.


6: Yang M, Zhan S, Fu L, Wang Y, Zhang P, Deng G. Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Drug Discov Ther. 2022 May 17;16(2):99-101. doi: 10.5582/ddt.2022.01025. Epub 2022 Apr 12. PMID: 35418550.


7: Li B, Liu Y, Luo J, Cai Y, Chen M, Wang T. Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment. Front Pharmacol. 2023 Apr 24;14:1157437. doi: 10.3389/fphar.2023.1157437. PMID: 37168994; PMCID: PMC10165100.


8: Wu X, Meng J, Yuan H, Zhong D, Yu J, Cao G, Liu X, Guo B, Chen Y, Li Y, Shi Y, Gordeev MF, Wu J, Zhang J. Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development. Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0040921. doi: 10.1128/AAC.00409-21. Epub 2021 Aug 16. PMID: 34398672; PMCID: PMC8522743.


9: Wang S, Cai C, Shen Y, Sun C, Shi Q, Wu N, Zheng S, Qian J, Zhang R, Zhou H. In vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, and Strains With Linezolid Resistance Genes From China. Front Microbiol. 2021 Aug 19;12:729900. doi: 10.3389/fmicb.2021.729900. PMID: 34489919; PMCID: PMC8417360.


10: Pi R, Chen X, Meng J, Liu Q, Chen Y, Bei C, Wang C, Gao Q. Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2022 Oct 18;66(10):e0103422. doi: 10.1128/aac.01034-22. Epub 2022 Oct 3. PMID: 36190243; PMCID: PMC9578412.


11: Wang W, Voss KM, Liu J, Gordeev MF. Nonclinical Evaluation of Antibacterial Oxazolidinones Contezolid and Contezolid Acefosamil with Low Serotonergic Neurotoxicity. Chem Res Toxicol. 2021 May 17;34(5):1348-1354. doi: 10.1021/acs.chemrestox.0c00524. Epub 2021 Apr 29. PMID: 33913699.


12: Guo W, Hu M, Xu N, Shangguan Y, Xia J, Hu W, Li X, Zhao Q, Xu K. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: A case report. Int J Antimicrob Agents. 2023 Aug;62(2):106875. doi: 10.1016/j.ijantimicag.2023.106875. Epub 2023 Jun 3. PMID: 37276894.


13: Wu J, Cao G, Wu H, Chen Y, Guo B, Wu X, Yu J, Ni K, Qian J, Wang L, Wu J, Wang Y, Yuan H, Zhang J, Xi Y. Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive- Controlled Crossover Study in Healthy Chinese Volunteers. Antimicrob Agents Chemother. 2020 May 21;64(6):e02158-19. doi: 10.1128/AAC.02158-19. PMID: 32229495; PMCID: PMC7269508.


14: Liu J, Wang W, Wang C, Zhang L, Zhang X, Liu S, Xu Y, Wang H, Dai Q, Liu C, Wang X, Yuan Z, Gordeev MF. Discovery of Antibacterial Contezolid Acefosamil: Innovative O-Acyl Phosphoramidate Prodrug for IV and Oral Therapies. ACS Med Chem Lett. 2022 Jun 29;13(7):1030-1035. doi: 10.1021/acsmedchemlett.2c00191. PMID: 35859881; PMCID: PMC9290071.


15: Wu J, Yang X, Wu J, Wang J, Wu H, Wang Y, Yuan H, Yang H, Wang H, Zhang J. Dose adjustment not required for contezolid in patients with moderate hepatic impairment based on pharmacokinetic/pharmacodynamic analysis. Front Pharmacol. 2023 Mar 13;14:1135007. doi: 10.3389/fphar.2023.1135007. PMID: 36992830; PMCID: PMC10040594.


16: Wang XK, Yu J, Xie CY, Hu XX, Nie TY, Li X, Wang PH, Li GQ, Yuan H, Yang XY, Li CR, You XF. In vivo pharmacodynamic study of contezolid acefosamil, a prodrug of contezolid for oral and intravenous administration. J Antimicrob Chemother. 2023 Jul 5;78(7):1632-1636. doi: 10.1093/jac/dkad138. PMID: 37202829.


17: Rodgers MP, Wertheim HFL. Comment on: A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections. J Antimicrob Chemother. 2022 Oct 28;77(11):3209-3210. doi: 10.1093/jac/dkac222. PMID: 35791752.


18: Zhao S, Zhang W, Zhang L, Zhang J, Li J, Si L, Ding Y, Li M, Song Y. Use of Contezolid for the Treatment of Refractory Infective Endocarditis in a Patient with Chronic Renal Failure: Case Report. Infect Drug Resist. 2023 Jun 13;16:3761-3765. doi: 10.2147/IDR.S413452. PMID: 37333679; PMCID: PMC10276592.


19: Wang Y, Wu H, Wu J, Fan Y, Liu X, Li Y, Hu J, Zhang J, Guo B. Development and validation of ultra-performance liquid chromatography-tandem mass spectrometric methods for simultaneous and rapid determination of contezolid and its major metabolite M2 in plasma and urine samples and its application to a study in subjects with moderate liver impairment. J Chromatogr B Analyt Technol Biomed Life Sci. 2022 Feb 15;1191:123129. doi: 10.1016/j.jchromb.2022.123129. Epub 2022 Jan 15. PMID: 35066246.


20: Zhao X, Huang H, Yuan H, Yuan Z, Zhang Y. A Phase III multicentre, randomized, double-blind trial to evaluate the efficacy and safety of oral contezolid versus linezolid in adults with complicated skin and soft tissue infections. J Antimicrob Chemother. 2022 May 29;77(6):1762-1769. doi: 10.1093/jac/dkac073. PMID: 35265985.